Start the car – what lies ahead over the next ten years and beyond…
For those pharma companies still in the UK – after Brexit, COVID, economic turmoil and the ongoing NHS crisis – be assured, the future still holds promise.
There are many factors that continue to make the NHS an attractive market and collaboration opportunity – its size, stability and large patient base, a statutory commitment to quality healthcare, and the potential for R&D partnerships and large-scale clinical studies, with diverse patient demographics.
Collaboration with the NHS provides industry with huge contracts and, in many cases, a single payer and point of negotiation for pricing and reimbursement.
Check out the rest of this feature here
Source link
#pharmas #future #PharmaTimes
